These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27329860)

  • 1. Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients.
    Kooistra HA; Piersma-Wichers M; Kluin-Nelemans HC; Veeger NJ; Meijer K
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):388-94. PubMed ID: 27329860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simic D; Skride A; Tang W; Trusz-Gluza M; Vesely J; Vishnepolsky T; Vrabec M
    Open Heart; 2020; 7(1):e001202. PubMed ID: 32257246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
    Choi EK; Lee YS; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D; Oh YS
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33184127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
    Renoux C; Coulombe J; Suissa S
    BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants].
    Fareau S; Baumstarck K; Farcet A; Molines C; Auquier P; Retornaz F
    Geriatr Psychol Neuropsychiatr Vieil; 2015 Mar; 13(1):45-54. PubMed ID: 25786423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
    Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation therapy in elderly patients with atrial fibrillation: results from the Registry of Atrial Fibrillation To Investigate the Implementation of New Guidelines (RAFTING).
    Pipilis A; Farmakis D; Kaliambakos S; Goudevenos J; Lekakis J;
    J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):545-549. PubMed ID: 26825445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
    Hengstenberg C; Van Mieghem NM; Wang R; Ye X; Shi L; Guo S; Chen C; Jin J; Ye X; Dangas G; Unverdorben M
    Am J Cardiol; 2023 Dec; 209():212-219. PubMed ID: 37848174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Contreras Muruaga MDM; Vivancos J; Reig G; González A; Cardona P; Ramírez-Moreno JM; Martí J; Suárez Fernández C;
    J Comp Eff Res; 2017 Jun; 6(4):303-312. PubMed ID: 28353372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.
    Coleman CI; Haas S; Turpie AG; Kuhls S; Hess S; Evers T; Amarenco P; Kirchhof P; Camm AJ;
    Clin Cardiol; 2016 Oct; 39(10):565-569. PubMed ID: 27362695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort.
    Pereira de Sousa L; Burba I; Ruperto C; Lattuada L; Barbone F; Di Chiara A
    J Cardiovasc Med (Hagerstown); 2013 Jul; 14(7):534-40. PubMed ID: 23328227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
    J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis.
    Lee SJ; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B
    Int J Cardiol; 2015 Feb; 180():185-91. PubMed ID: 25463361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study.
    Gussoni G; Di Pasquale G; Vescovo G; Gulizia M; Mathieu G; Scherillo M; Panuccio D; Lucci D; Nozzoli C; Fabbri G; Colombo F; Riva L; Baldo CI; Maggioni AP; Mazzone A;
    Eur J Intern Med; 2013 Jun; 24(4):324-32. PubMed ID: 23684591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.